Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 40

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NVE5

UPID:

UBP40_HUMAN

Alternative names:

Deubiquitinating enzyme 40; Ubiquitin thioesterase 40; Ubiquitin-specific-processing protease 40

Alternative UPACC:

Q9NVE5; Q6NX38; Q70EL0

Background:

Ubiquitin carboxyl-terminal hydrolase 40, also known as Deubiquitinating enzyme 40, Ubiquitin thioesterase 40, and Ubiquitin-specific-processing protease 40, is a protein encoded by the gene with the accession number Q9NVE5. It is suggested to be catalytically inactive, indicating a unique role in cellular processes distinct from traditional enzymatic activities.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 40 could open doors to potential therapeutic strategies. Its unique position in cellular mechanisms makes it a compelling target for drug discovery, aiming to modulate its function for therapeutic benefits.